Exudative Macular Degeneration
Conditions
Brief summary
We propose to undertake a retrospective review of approximately 200 patients with a diagnosis of exudative macular degeneration treated with triple combination therapy (Bevacizumab, Dexamethasone and Photo-dynamic therapy) during the years of 2006 to 2010 at The Retina Center and compare those results with an additional group of approximately 200 patients also treated with triple combination therapy and 20 mg of daily oral zeaxanthin.
Detailed description
Study parameters will include best corrected visual acuity, number of combination treatments, reduction of central foveal thickness by OCT measurement and development of exudative macular degeneration in the fellow eye. Follow up will include all patients with a minimum of two years. Retrospective review of patient charts in the office of The Retina Center.
Interventions
PROCEDURETRIPLE COMBINATION THERAPY
TREATMENT WITH BEVACIZUMAB, DEXAMETHASONE AND PHOTODYNAMIC THERAPY
Sponsors
The Retina Center of St. Louis County, PC
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No
Inclusion criteria
\- MUST HAVE AGE RELATED MACULAR DEGENERATION
Exclusion criteria
\-
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| BEST CORRECTED VISUAL ACUITY | REVIEW OF EXAMINATION SHEETS |
Secondary
| Measure | Time frame |
|---|---|
| NUMBER OF COMBINATION TREATMENTS | REVIEW OF CHART |
| REDUCTION OF CENTRAL FOVEAL THICKNESS BY OCT MEASUREMENT | REVIEW OF CHART |
| DEVELOPMENT OF EXUDATIVE MACULAR DEGENERATION IN THE FELLOW EYE | REVIEW OF CHART |
Countries
United States
Outcome results
None listed